{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:05:26Z","timestamp":1784430326181,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.radonc.2025.110955","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:34:11Z","timestamp":1748111651000},"page":"110955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Second primary cancer risks in seminoma patients treated with current and previous radiotherapy protocols: a systematic literature review"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2144-0729","authenticated-orcid":false,"given":"Wilma D.","family":"Heemsbergen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Spampinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Dirkx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Jahrei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost L","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Franckena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-279X","authenticated-orcid":false,"given":"Liesbeth J.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110955_b0005","first-page":"3752","article-title":"Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up","volume":"30","author":"Haugnes","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0010","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.annonc.2023.09.3101","article-title":"Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective","volume":"34","author":"Foss\u00e5","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0015","first-page":"81","article-title":"Prognostic Factors for Relapse in Patients With Clinical Stage I Testicular Seminoma: A Nationwide","volume":"42","author":"Wagner","year":"2024","journal-title":"Population-Based Cohort Study J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology Guidelines on Testicular Cancer: 2023 Update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.110955_b0025","article-title":"FU Cancer Committee Guidelines - Update 2024-2026: Testicular germ cell cancer","volume":"34","author":"Murez","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.radonc.2025.110955_b0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0959-8049(96)00458-3","article-title":"Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients","volume":"33","author":"Wander\u00e5s","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1464-410X.2011.10424.x","article-title":"Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma","volume":"109","author":"Lewinshtein","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2025.110955_b0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries","volume":"12","author":"Berrington de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0045","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1007\/s00345-023-04674-8","article-title":"Advances in radiation therapy for testicular seminoma","volume":"41","author":"Rosen","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2025.110955_b0050","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/j.ijrobp.2012.01.044","article-title":"Radiotherapy treatment planning for testicular seminoma","volume":"83","author":"Wilder","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0055","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmp.2017.02.015","article-title":"Models for the risk of secondary cancers from radiation therapy","volume":"42","author":"Dasu","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.radonc.2025.110955_b0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4682-8-27","article-title":"Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy","volume":"8","author":"Schneider","year":"2011","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.radonc.2025.110955_b0065","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.118.217182","article-title":"Are We Approaching the End of the Linear No-Threshold Era?","volume":"59","author":"Doss","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2025.110955_b0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13629-023-00406-0","article-title":"Protonentherapie voor seminoma testis","volume":"13","author":"Sinnige","year":"2023","journal-title":"Tijdschr Urol"},{"key":"10.1016\/j.radonc.2025.110955_b0075","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.110955_b0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.radonc.2025.110955_b0085","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/jnci\/89.19.1429","article-title":"Risk of second malignant neoplasms among long-term survivors of testicular cancer","volume":"89","author":"Travis","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2025.110955_b0090","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jnci\/dji278","article-title":"Second cancers among 40,576 testicular cancer patients: focus on long-term survivors","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2025.110955_b0095","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"25","author":"Van den Belt-Dusebout","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2013.551","article-title":"Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma","volume":"110","author":"Horwich","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0105","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jamaoncol.2016.3651","article-title":"Second malignant neoplasms and cause of death in patients with germ cell cancer: a danish nationwide cohort study","volume":"2","author":"Kier","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0110","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2017.77.4174","article-title":"Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era","volume":"36","author":"Groot","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ijc.32704","article-title":"Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era","volume":"147","author":"Hellesnes","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa017","article-title":"Solid and hematologic neoplasms after testicular cancer: a US population-based study of 24\u2009900 survivors","volume":"4","author":"Milano","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.radonc.2025.110955_b0125","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/cncr.28086","article-title":"Outcomes in stage I testicular seminoma: a population-based study of 9193 patients","volume":"119","author":"Beard","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/cncr.32538","article-title":"Platinum exposure and cause-specific mortality among patients with testicular cancer","volume":"126","author":"Groot","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/bjc.2014.552","article-title":"Increased stomach cancer risk following radiotherapy for testicular cancer","volume":"112","author":"Hauptmann","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0140","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/bjc.2016.272","article-title":"Increased pancreatic cancer risk following radiotherapy for testicular cancer","volume":"115","author":"Hauptmann","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0145","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/0284186X.2011.564650","article-title":"Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma","volume":"50","author":"Zilli","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.radonc.2012.01.012","article-title":"Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk","volume":"103","author":"Efstathiou","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijrobp.2010.11.021","article-title":"Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma","volume":"82","author":"Simone","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14338\/IJPT-20-00018.1","article-title":"Outcomes and toxicities of proton and photon radiation therapy for testicular seminoma","volume":"7","author":"Pasalic","year":"2020","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.radonc.2025.110955_b0165","article-title":"Cancer control, toxicity, and secondary malignancy risks of proton radiation therapy for stage I-IIB testicular seminoma","volume":"8","author":"Maxwell","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0170","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1080\/0284186X.2023.2254925","article-title":"Dose comparison of robustly optimized intensity modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for testicular seminoma","volume":"62","author":"R\u00f8nde","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0175","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/cancers16040784","article-title":"Radiation Therapy for Stage IIA\/B Seminoma: Modeling Secondary Cancer Risk for Protons and VMAT versus 3D Photons","volume":"16","author":"Pursley","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110955_b0180","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1118\/1.4932394","article-title":"Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model","volume":"42","author":"Mazonakis","year":"2015","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0185","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1667\/RR14492.1","article-title":"Solid cancer incidence among the life span study of atomic bomb survivors: 1958-2009","volume":"187","author":"Grant","year":"2017","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.110955_b0190","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ijc.22345","article-title":"Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries","volume":"1","author":"Richiardi","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0195","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jnci\/djq525","article-title":"Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up","volume":"103","author":"Mead","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2025.110955_b0205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2012.12.002","article-title":"Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields","volume":"106","author":"Paly","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0210","doi-asserted-by":"crossref","first-page":"v140","DOI":"10.1093\/annonc\/mdq176","article-title":"Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Schmoll","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0215","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ucl.2024.03.008","article-title":"Contemporary role of radiation therapy in testicular cancer","volume":"51","author":"Shiao","year":"2024","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.radonc.2025.110955_b0220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0360-3016(89)90334-9","article-title":"Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients","volume":"16","author":"Foss\u00e5","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0225","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/j.ijrobp.2012.01.044","article-title":"Radiotherapy treatment planning for testicular seminoma","volume":"15","author":"Wilder","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0230","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jso.2930250406","article-title":"Is mediastinal irradiation necessary for stage I testicular seminoma?","volume":"25","author":"Jose","year":"1984","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/COC.0b013e318254950a","article-title":"Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis","volume":"36","author":"Jones","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.euo.2023.10.014","article-title":"Prognostic factor risk groups for clinical stage i seminoma: an individual patient data analysis by the european association of urology testicular cancer guidelines panel and guidelines office","volume":"7","author":"Boormans","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0245","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejmp.2017.02.013","article-title":"Photons - Radiobiological issues related to the risk of second malignancies","volume":"42","author":"Marcu","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.radonc.2025.110955_b0250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0360-3016(03)00073-7","article-title":"Radiation-induced second cancers: the impact of 3D-CRT and IMRT","volume":"56","author":"Hall","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0255","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0260","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0360-3016(01)02826-7","article-title":"Secondary neutron dose during proton therapy using spot scanning","volume":"53","author":"Schneider","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2015.00261","article-title":"Secondary Malignancy Risk Following Proton Radiation Therapy","volume":"5","author":"Eaton","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0270","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ijrobp.2018.03.002","article-title":"The Children's oncology group radiation oncology discipline: 15 years of contributions to the treatment of childhood cancer","volume":"101","author":"Breneman","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jrr\/rrad090","article-title":"Revolutionizing radiation therapy: the role of AI in clinical practice","volume":"65","author":"Kawamura","year":"2024","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2025.110955_b0280","article-title":"Linear Non-Threshold (LNT) historical discovery milestones","volume":"113","author":"Calabrese","year":"2022","journal-title":"Med Lav"},{"key":"10.1016\/j.radonc.2025.110955_b0285","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/HP.0000000000001775","article-title":"If you torture your data long enough, it will confess to anything: on the epidemiological basis of the LNT model","volume":"126","author":"Socol","year":"2024","journal-title":"Health Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0290","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clon.2016.11.002","article-title":"Cobalt-60 machines and medical linear accelerators: competing technologies for external beam radiotherapy","volume":"29","author":"Healy","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.110955_b0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)53602-2","article-title":"Treatment of testicular tumors arising in patients with previous inguinal and\/or scrotal surgery","volume":"127","author":"Lanteri","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2025.110955_b0300","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0360-3016(87)90122-2","article-title":"Stage I testicular seminoma: Rationale for postorchiectomy radiation therapy","volume":"13","author":"Zagars","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110955_b0305","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1038\/sj.bjc.6601867","article-title":"Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG)","volume":"90","author":"Classen","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110955_b0310","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eururo.2011.05.038","article-title":"EAU guidelines on testicular cancer: 2011 update","volume":"60","author":"Albers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2025.110955_b0315","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2017.06.051","article-title":"Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival","volume":"35","author":"Patel","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0320","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.radonc.2005.08.005","article-title":"Towards individualised radiotherapy for Stage I seminoma","volume":"76","author":"Martin","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110955_b0325","doi-asserted-by":"crossref","unstructured":"Choo R, Kazemba B, Choo CS, Lester SC, Whitaker T. Proton therapy for stage IIA-B seminoma: a new standard of care for treating retroperitoneal nodes. Int J Part Ther 2018;5:50\u201357. https:\/\/doi.org\/10.14338\/ IJPT-18-00001.1.","DOI":"10.14338\/IJPT-18-00001.1"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025044597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025044597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:21:10Z","timestamp":1761128470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025044597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":65,"alternative-id":["S0167814025044597"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110955","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second primary cancer risks in seminoma patients treated with current and previous radiotherapy protocols: a systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110955"}}